Allergen immunotherapy (AIT) has been used to treat allergic disease since the early 1900s. Despite numerous clinical trials and meta-analyses proving AIT efficacious, it remains underused and is estimated to be used in less than 10% of patients with allergic rhinitis or asthma worldwide. In addition, there are large differences between regions, which are not only due to socioeconomic status. There is practically no controversy about the use of AIT in the treatment of allergic rhinitis and allergic asthma, but for atopic dermatitis or food allergy, the indications for AIT are not well defined. The elaboration of a wider consensus is of utmost importance because AIT is the only treatment that can change the course of allergic disease by preventing the development of asthma and new allergen sensitizations and by inducing allergen-specific immune tolerance. Safer and more effective AIT strategies are being continuously developed both through elaboration of new allergen preparations and adjuvants and alternate routes of administration. A number of guidelines, consensus documents, or both are available on both the international and national levels. The international community of allergy specialists recognizes the need to develop a comprehensive consensus report to harmonize, disseminate, and implement the best AIT practice.
INTRODUCTION Aim
The international consensus statement on allergen immunotherapy (AIT) is a concise document authored by a multinational group of experts reviewing the pertinent literature and summarizing the key statements for AIT. The document combines the best scientific evidence with expert opinion consensus and was developed to serve as the resource for health care professionals managing patients with allergic diseases. The document also provides a rationale for providing better access to AIT based on the public health and pharmacoeconomic analyses that can be used by policymakers. It is adaptable for all countries worldwide, allowing for modifications based on the regional availability of diagnostic and therapeutic interventions.
Methodology of the international consensus on AIT
The current board of the International Collaboration in Asthma, Allergy and Immunology and the participating organizations formed the working committee on the basis of regional representation, expertise in the field, and previous participation in the creation of AIT guidelines. The members of the committee proposed the most relevant areas and selected the documents for critical review; the major documents are listed in Table I . Many task force reports and consensus documents of the European Academy of Allergy and Clinical Immunology (EAACI) AIT Interest Group, as well as key scientific papers, were also considered. Each member was responsible for the preparation of text. A draft was subsequently compiled and circulated (in January 2015) among the authors for comments and corrections. The governing boards of the participating organizations then approved the final draft. The nomenclature and terms used are summarized in Box 1.
Current status of AIT
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Increasingly, health care payers and regulators are asking for greater detail about the clinical benefit that can be achieved, and to that end, we need better systems for defining benefit not only in 33 Recently, an EAACI Task Force recommended a homogeneous combined symptom and medication score as the primary outcome for AIT effectiveness, which provides a simple and standardized method that balances both symptoms and the need for antiallergic medication in an equally weighted manner. 34 On the other hand, reliable systems of allergen exposure are needed to assess AIT-induced allergen-specific tolerance. In this context environmental exposure chambers provide a very promising approach. 35 
METHODS OF AIT Routes of administration
Subcutaneous injection has been the predominant method of administration. Over the last 2 decades, sublingual application of the extracts has increased and is now the dominant approach in several European countries. 36 Additional approaches to AIT under active investigation include epicutaneous and intralymphatic administration.
37,38

Administration regimens
The conventional schedule for SCIT with unmodified allergen extracts consists of a dose build up by means of one-weekly injections, followed by maintenance dose injections at 4-or 8-week intervals. Fewer build-up injections are possible with modified allergenic extracts, such as allergoids or addition of adjuvants.
The build-up phase can be shortened by using cluster or rush schedules. During a cluster schedule, multiple injections (usually 2-3) are administered on nonconsecutive days. In a rush protocol multiple injections are administered on consecutive days, reaching maintenance typically in 1 to 3 days. A direct comparison showed no increase in systemic reactions (SRs) and a more rapid achievement of symptomatic improvement for the cluster schedule. 39 A rush protocol, on the other hand, even with use of premedication, is associated sometimes with an increase in SRs but can also be well tolerated. 32, 40, 41 In SLIT the build-up period is either shortened or not needed.
Treatment duration
The customary duration of AIT is 3 to 5 years. Prospective studies of SCIT with grass pollen extract for allergic rhinitis (AR) 42 and house dust mite (HDM) extract for asthmatic patients 43 suggest that 3 years of AIT produces prolonged remission of symptoms after discontinuation. A prospective study of SLIT with HDM extract in patients with AR demonstrated remissions lasting 7 and 8 years, respectively, with 3 or 4 years of active treatment. 44 
Special considerations
Polysensitized patients. The majority of patients with AR or allergic asthma seen by specialists are polysensitized. Not all of these sensitivities are clinically important. Moreover, AIT is equally effective in monosensitized and polysensitized patients if the relevant allergen is selected. 45 Monoallergen immunotherapy versus allergen mixes. Virtually all of the published randomized controlled studies of both SCIT and SLIT are with single allergen extracts. These studies dominate the meta-analyses that indicate both SCIT and SLIT are effective treatments for AR and allergic asthma. There is conflicting evidence for the effectiveness of allergen mixes.
46-48
Selection of allergens for AIT. Relevant allergens are major contributors to the safety and efficacy of the allergenic extracts used for AIT. Most of the available data address mites, selected pollens, and animal dander, whereas less is known about the efficacy and safety of mold or cockroach allergens. Selection of the relevant allergen is usually based on the combination of history with results of skin prick or in vitro tests. Component-resolved diagnosis might prove useful for excluding cross-reactive allergens.
Multiple AIT products. An alternative to allergen mixes for both SLIT and SCIT is the administration of multiple allergen extracts at different times during the day or different locations. 45 
SPECIFIC CLINICAL INDICATIONS FOR AIT AR
Indications and efficacy. According to the Allergic Rhinitis and its Impact on Asthma guidelines, 25, 49 AIT is indicated for the treatment of moderate-to-severe intermittent or persistent symptoms of AR, especially in those who do not respond well to pharmacotherapy. Allergen extracts are available for grass, tree, and weed (ie, ragweed) pollens; HDMs; mold; and animal dander. Standardized extracts should be used in clinical practice because the efficacy and safety of AIT depends strictly on extract quality.
Recent systematic reviews have consistently shown that AIT can achieve substantial clinical results by improving nasal and ocular symptoms and by reducing medication need.
11,20,50-52 AIT also improves quality of life, prevents progression of AR to asthma, and reduces new sensitizations. [53] [54] [55] Clinical efficacy persists after discontinuation of AIT. 44, 56 All the outcomes of AIT in patients with AR lead to a clear pharmacoeconomic advantage over other therapies. 57 Contraindications and side effects SCIT requires that injections should be performed by trained personnel in clinical settings who are equipped to manage any possible systemic adverse reactions or anaphylaxis. SRs are quite rare when AIT is performed according to proper safety recommendations. [58] [59] [60] AIT is contraindicated in patients with medical conditions that increase the risk of treatment-related severe SRs, such as those with severe or poorly controlled asthma or significant cardiovascular diseases (eg, unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension) and should be administered with caution to patients receiving b-blockers or angiotensin-converting enzyme inhibitors. 13 Chronic nasal inflammatory responses and nasal polyps are not a contraindication for AIT.
Measuring clinical outcome. Symptom and medication scores are the recommended measure of efficacy for randomized controlled trials, particularly the combined symptom and medication score. For clinical practice, the visual analog scale or the newly developed rhinitis control tests might be more helpful. However, standardized and globally adopted measures of AIT efficacy in randomized controlled trials are still lacking. 34 Treatment duration. The recommended duration of AIT for AR is 3 years both for SCIT and SLIT. Evidence from a long-term open controlled study suggests that a 3-year course of SLIT might not be sufficient for a long-term protection. 44 Pediatric considerations. SLIT is shown to be safe and effective, even in children as young as 3 years of age.
11,20,52
A meta-analysis of SLIT in children reported significantly J ALLERGY CLIN IMMUNOL VOLUME 136, NUMBER 3 reduced symptoms and medication scores. 61 However, criteria for new well-designed and well-powered studies in children are requested by the European Medicines Agency within the pediatric investigations plan, with an emphasis on long-term efficacy.
Allergic asthma
The pathologic process of airways inflammation in asthmatic patients is not invariably associated with atopy. Within the allergic asthma subgroup, the pathophysiology is very complex and includes several disease variants. 59 Various endotypes have been described that define intrinsically distinct pathogenetic mechanisms. Endotyping asthma could eventually lead to individualized management, including selection of asthmatic patients responding best to AIT. 62 Current asthma therapies can effectively control symptoms and the ongoing inflammatory process but do not affect the underlying dysregulated immune response. 63 Thus they are very limited in controlling the progression of the disease.
Indications and efficacy. The current Allergic Rhinitis and its Impact on Asthma guidelines 25, 49 give both SCIT and SLIT a conditional recommendation in patients with allergic asthma because of the moderate or low quality of evidence. According to the Global Initiative for Asthma report updated in 2014, 64 the efficacy of AIT in asthmatic patients is limited (level A evidence), and compared with pharmacologic and avoidance options, the benefit of both SCIT and SLIT must be weighed against the risk of side effects and the inconvenience and cost incurred by the prolonged course of treatment (level D evidence).
Few specifically designed studies evaluated AIT in asthmatic patients, and only 1 had a formal sample size calculation. 65 In addition, no consensus exists on the optimal end points, with pulmonary function or asthma exacerbations or control assessed as the primary outcome only sporadically. Several double-blind, placebo-controlled trials and meta-analysis (potentially hampered by the heterogeneity of the trials included) have confirmed that both SCIT and SLIT are of value in patients with allergic asthma associated with AR. An effectiveness and safety review conducted by the US Food and Drug Administration 66 showed moderate to high (somewhat weaker in children) evidence for the efficacy of both SCIT and SLIT in asthmatic patients, with weak evidence for assessing the superiority of either route. One Cochrane review 67 reported a significant reduction in symptom scores, medication use, and allergen-specific airway hyperreactivity and a limited reduction in nonspecific airway hyperreactivity. The effects on lung function were not consistent among trials. The most recent systematic review up to May 2013 concluded that SCIT significantly reduces asthma symptoms and medication use. 68 Because most of the published evidence for SLIT comes from studies primarily in patients with rhinitis, they are not adequately powered. A systematic review on SLIT reports strong evidence for improvement in asthma symptoms versus the comparator but only moderate evidence for a decrease in use of asthma medication. 69 A potential steroid-sparing effect of AIT is of utmost importance to avoid the potential side effects of inhaled corticosteroids in asthmatic patients. For both SCIT and SLIT, a reduction of the inhaled corticosteroid dose needed to maintain asthma control was demonstrated. 65, 70, 71 Ongoing phase 3 confirmatory double-blind, placebocontrolled trials with both SCIT and SLIT in patients with perennial HDM allergic asthma will provide more robust evidence (data from ClinicalTrials.gov, EU Clinical Trials Register, Japan Pharmaceutical Information Center: Clinical Trials Information).
Contraindications and side effects. Severe or uncontrolled asthma is the major independent risk factor for both nonfatal and fatal adverse reactions and thus a major contraindication for both SLIT and SCIT. 13, 45, 72 All patients undergoing AIT should be observed typically for at least 30 minutes after injection to ensure proper management of SRs. 13 Measuring clinical outcomes. Most of the clinical trials evaluated clinically relevant parameters, such as symptom and medication scores (with an emphasis on the corticosteroid sparing effect) and lung function. According to the European Medicines Agency, clinical trials on AIT in asthmatic patients start as add-on therapy, which has to be considered in the evaluation of the primary end point (eg, evaluation in the context of a stepwise reduction in controller medication). Lung function, composite scores, number of exacerbations, and reduced need for controller medication could be considered primary end points.
Treatment duration. The duration of AIT is still a matter of debate. A recent study in asthmatic children showed that that 3 years of SCIT is an adequate duration for the treatment of asthma in patients with HDM allergy. 73 Pediatric considerations. A systematic review evaluating the evidence regarding the efficacy and safety of SCIT and SLIT for the treatment of pediatric asthma and allergic rhinoconjunctivitis concluded that SCIT reduces symptoms and medication scores, whereas SLIT can improve asthma symptoms. 60 A meta-analysis of SLIT in children reported moderate effectiveness on asthma symptoms and medication intake. 74 New well-controlled studies are requested by the European Medicines Agency within the pediatric investigations plan.
AD
Indications and efficacy. There is still controversy about the potential role of AIT as a therapeutic intervention for patients with AD and aeroallergen sensitivity. Case reports and smaller cohort studies showed some positive effects of AIT on skin conditions. A large dose-finding phase II study in HDMsensitized patients with AD 75 showed a significant SCORAD score decrease after 8 weeks, and the effect was maintained over 1 year, including lower glucocorticosteroid use. A recent meta-analysis proved moderate-level evidence of efficacy. 76 However, the largest prospective placebo-controlled study included in this meta-analysis showed efficacy only in severely affected patients (SCORAD score >50). 77 A recent systematic review with the Grading of Recommendations Assessment, Development and Evaluation system reported improvement in clinical symptoms. 78 Serious methodological shortcomings were noted, such as many dropouts, small study size; incomplete descriptions of randomization, blinding, and allocation concealment; and data analysis not by the intention-to-treat principle. The only SLIT study performed with HDM allergens in children with AD described a positive outcome only in those with mild-to-moderate disease. 79 Contraindications and side effects. There is no contraindication for AIT in patients with respiratory allergic diseases (allergic rhinoconjunctivitis and mild allergic asthma) associated with AD. Eczema is not worsened during or after AIT. 29, 80 Food allergy
The first case of oral immunotherapy (OIT) to treat food allergy reported in Lancet in 1908 81 offers an accurate description of an episode of severe anaphylaxis on exposure of a child to egg. The demonstration that large amounts of egg can be tolerated after gradual desensitization followed by long-term maintenance with continued consumption of egg raises the question of how long OIT needs to continue. 81 These issues are more pertinent than ever, with a growing number of publications and research into immunotherapy for food allergy.
Early studies of SCIT to peanut were discontinued because of the high rate of anaphylactic reactions. More recently, studies using OIT or SLIT to peanut, milk, and egg have shown promise. [82] [83] [84] [85] [86] [87] [88] Recently, a first safety trial has been performed with a hypoallergenic mutant of fish parvalbumin in SCIT for the treatment of fish allergy. 89 OIT using raw or heat-modified food appears to be more effective than SLIT. 90 A high proportion of patients were able to pass an oral food challenge after 1 to 4 years of OIT with a 20-to 100-fold increase in threshold reactivity and daily ingestion of high maintenance doses (300-4000 mg) of the food protein.
However, the rate of SRs requiring epinephrine, which were observed in up to 25% of participants, especially those using raw food, is still too high for recommending OIT in daily practice. With SLIT, the doses are much lower (<10 mg/d), and the safety profile is better, but the threshold of reactivity reached at the end of the treatment is usually lower, affecting efficacy. Although increased food-specific IgG levels and decrease in basophil activation are observed during immunotherapy, there are currently no biomarkers to predict the response. Efficacy can only be demonstrated through sequential oral food challenges.
A good response is associated with a longer AIT duration and a larger amount of food tolerated. Associated treatments, such as omalizumab, can reduce adverse reactions and improve efficacy. 91 Food immunotherapy can induce desensitization that would require continuous therapy. Whether food immunotherapy can induce long-term tolerance in which therapy can be discontinued indefinitely is unknown. Two studies have shown sustained unresponsiveness to egg and peanut after OIT in only 28% and 50% of cases. 90, 92, 93 In another peanut OIT study, 94 only 3 of 7 patients successfully desensitized after 3 months of treatment withdrawal remained unresponsive for an additional 3 months. There is evidence that children who tolerate baked milk and egg can outgrow their food allergies independent of attempted therapeutic measures. 95, 96 An improvement in quality of life has been suggested, but the risk-taking behavior encouraged by the false sense of security provided by treatment was not evaluated.
Because of the risk of adverse reactions, including anaphylaxis, EAACI guidelines do not recommend food AIT for routine clinical use (level III, grade D). The procedure should be performed only in highly specialized centers with expert staff and adequate equipment and in accordance with clinical protocols approved by local ethics committees. 96, 97 
SAFETY OF AIT
Adverse reactions associated with AIT can be local or systemic. Local reactions (LRs) are fairly common with both SCIT (erythema, pruritus, and swelling at the injection site) and SLIT (oropharyngeal pruritus, swelling, or both), affecting up to 82% of patients receiving SCIT 13 and 75% of patients receiving SLIT. 98 Gastrointestinal symptoms associated with SLIT can be classified as LRs (if only associated with Most SLIT-related LRs occur shortly after treatment initiation and cease within days to a few weeks without any medical intervention. Although the overall dropout rate in double-blind, placebo-controlled trials was similar to that with placebo, 99 dropouts because of adverse events were significantly greater in the SLIT group. A 3-grade classification system for SLIT LRs based on the patient's subjective accounting was developed by a WAO task force with the intent of improving and harmonizing the surveillance and reporting of SLIT safety. 100 Treatment discontinuation caused by LRs (grade 3 reaction) is one of the major determinants of the LR severity grade in this classification system. With this same aim, a previous WAO document proposed a grading system for SCIT. 101 
Box 1. Nomenclature and terms
Anaphylaxis: Immediate systemic reaction, often occurring within minutes and occasionally as long as an hour or longer after exposure to an allergen.
Allergen immunotherapy (AIT):
Procedure inducing tolerance to a specific allergen through repetitive administration of an allergen.
Allergic rhinitis (AR):
Inflammation of the nasal mucosa induced on exposure to an allergen together with proof of immunologic sensitization to that allergen.
Allergic asthma: Typical symptoms of asthma (wheezing, cough, dyspnea, and chest tightness) induced on exposure to an allergen together with proof of immunologic sensitization to that allergen.
Build-up phase: Period of AIT in which increasing amounts of allergen are administered until a maintenance dose is reached.
Cluster immunotherapy: An accelerated build-up schedule that allows reaching the maintenance dose more rapidly.
Combined symptom and medication score (CSMS): Standardized method that balances both symptoms and the need for antiallergic medication in an equally weighted manner.
Homologous allergen groups: Allergen extracts prepared from different species, different genera, or different families and finished products that are derived from these allergen extracts for which clinical experience already exists and fulfill the criteria provided by the European Medicines Agency.
Local reaction (LR):
Inflammatory response confined to the contact site.
Oral immunotherapy (OIT): Oral route of allergen administration to induce tolerance.
Oral food challenge (OFC): Provocation test used for the diagnosis of food allergy.
Pediatric investigation plan (PIP): Development plan aimed at ensuring that appropriate pediatric studies are performed to obtain the necessary quality, safety, and efficacy data to support the authorization of a medicine for use in children.
Systemic allergic reaction (SR):
Triggered by AIT vaccine administration.
Subcutaneous immunotherapy (SCIT): Subcutaneous injectable route of allergen administration.
Sublingual immunotherapy (SLIT): Sublingual (drops or tablets) route of allergen administration.
Box 2. Key messages
d Better selection of responders based on an endotype-driven strategy is desired to increase both efficacy and safety.
d High-quality studies are needed to answer questions regarding optimal dosing strategies, disease-modifying potential, and cost-effectiveness over the standard of care.
d AIT achieves substantial clinical results in patients with AR by improving nasal and ocular symptoms and reducing medication need, improving quality of life, preventing progression of AR to asthma, and reducing new sensitizations.
d SLIT and SCIT can be used in patients with mild and moderate asthma associated with allergic rhinoconjunctivitis provided that asthma is controlled by pharmacotherapy.
d A measurable clinical benefit on asthma symptoms and a steroid-sparing effect is expected.
d AIT cannot be presently recommended as single therapy when asthma is the sole manifestation of respiratory allergy.
d Medical conditions that reduce the patient's ability to survive the systemic allergic reaction or that make the resultant treatment a relative contraindication for AIT must be identified. Examples include severe asthma uncontrolled by pharmacotherapy and significant cardiovascular disease.
d There is no contraindication for AIT in patients with respiratory allergic diseases (allergic rhinoconjunctivitis and mild allergic asthma) associated with AD.
d AIT might have positive effects in selected sensitized patients with AD; the best evidence is available for HDM AIT.
d Patients with a positive IgE test response and corresponding history of eczema triggered by a clearly defined allergen are potential candidates for AIT in the setting of AD.
d For food allergy, an EAACI systematic review of the literature highlighted a large heterogeneity in the protocols used by different research groups in terms of preparation of food allergens, updosing, maintenance dose, and OFC procedure; therefore there is no single established protocol that has been shown to be both effective and safe in large multicenter studies.
d Currently, there is agreement that although immunotherapy to foods is an important area of research, it is not yet ready for clinical practice.
d Some risk factors for SCIT-induced severe SRs have been identified, but none have been clearly established for SLIT.
d Both SLIT and SCIT have acceptable safety profiles if administered under the appropriate circumstances. SLIT's more favorable safety profile allows for administration outside of a medically supervised setting, whereas SCIT is recommended only in a medically supervised setting with appropriate staff and equipment to identify and immediately treat anaphylaxis.
d Consistent use of the uniform classification systems for grading AIT-related (SLIT and SCIT) SRs and LRs both in clinical trials and surveillance studies will allow better comparisons and best practices for all AIT treatments.
LRs were ''deemed not bothersome at all or only slightly bothersome'' by 82% of SCIT survey respondents, with only 4% indicating they would stop SCIT because of the LR. 102 LRs are not predictive of subsequent SRs with either AIT route. 103, 104 No study found that increased frequency of large SCIT LRs increases the risk for future SRs. 105 SCIT-related SRs can range in severity from mild to lifethreatening or fatal anaphylaxis. The incidence of SCIT SRs varies depending on the induction schedule, augmenting factors, premedication, and the degree of sensitization. In most surveys the rate of SRs with nonaccelerated SCIT induction is approximately 0.1% to 0.2% of injections and 2% to 5% of patients.
101,106 A 5-grade classification system based on reaction severity and the organ system or systems involved was developed in 2010 for reporting of AIT-related SRs (SCIT and SLIT). 104 In a 4-year AIT safety survey that included 23.3 million injection visits, the SR rate was consistently 0.1% of injection visits, with 97% of the SRs being classified as mild or moderate in severity. 106, 107 The incidence of severe SRs was approximately 1 in one million injections, which is similar to previous surveys. 58 There was 1 confirmed SCIT-related fatality in this survey. In previous surveys there was an estimated rate of 3 to 4 SCIT-related fatalities per year, which translated to a fatality rate of 1 in 2 to 2.5 million SCIT injections. 105 Risk factors for SCIT-related SRs include symptomatic asthma, prior SCIT-related SRs, and a high degree of skin test reactivity. 13 Other potential risk factors for SCIT-related SRs, such as administration during the height of the pollen season, updosing schedule (cluster vs conventional), and treatment phase (maintenance vs updosing), have been suggested, but none have been clearly established. 106, 108 Symptomatic or poorly controlled asthma was identified as a contributing factor in most fatal and near-fatal SCIT-related SRs. 106 It has been suggested that better safety measures, especially regarding asthma assessment before SCIT injections, might be a factor in the reduced fatality rates seen in the most recent AIT survey. 109 Compared with SCIT, the SLIT-related SR rate is significantly lower, and severe SRs are relatively uncommon. In a comprehensive review of 104 SLIT studies published through October of 2005, the SLIT-related SR rate was 0.056% of doses administered (ie, 14 probable SLIT-related serious adverse events, which translated to 1.4 serious adverse events per 100,000 SLIT administered doses). 98 To date, there have been no confirmed reports of SLIT-related fatalities, but SRs of a severity to be categorized as anaphylaxis have been reported. 72 In a few of the anaphylaxis cases, the subjects had experienced an SR in an earlier SCIT treatment course, 2 of whom had SRs with their first SLIT dose. 110 No clear predictors for SLIT-related SRs have been established. Unlike SCIT, the incidence of SRs does not appear to be related to induction schedule, allergen dose, symptomatic asthma, or degree of sensitization. Because SLIT is administered in a setting without direct medical supervision, specific patient instructions should be provided regarding management of adverse reactions and the clinical scenarios when the administration of SLIT should be postponed (eg, asthma exacerbation, acute gastroenteritis, and stomatitis or esophagitis). SLIT for environmental pollen has been associated with the onset of eosinophilic esophagitis. 111 In addition, OIT for food allergy can trigger eosinophilic esophagitis. 112 SLIT's more favorable safety profile allows for administration outside of a medically supervised setting, whereas SCIT's greater risks recommend administration only in a medically supervised setting with appropriate staff and equipment to identify and immediately treat anaphylaxis. 7, 68 This recommendation is consistent with US-licensed allergenic extract package insert's black box warning. 113 
CONCLUSIONS AND UNMET NEEDS
The key messages of this position statement are summarized in Box 2. AIT is effective in reducing symptoms of allergic asthma and rhinitis and potentially modifies the underlying course of disease. Studies on AIT in the treatment of AD and food allergy could broaden the indications. However, AIT remains underused because of a lack of awareness, limited access to specialist care, the reimbursement policy, long duration, and concerns regarding safety and effectiveness (Fig 1) . The major barrier for the further development of AIT, especially for the new technologies, is the capacity to perform 1 or more phase 3 confirmatory double-blind, placebo-controlled trials per allergen source. Several unmet needs have been identified (Box 3).
